FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 235 filers reported holding FATE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $59,360 | -55.5% | 28,000 | 0.0% | 0.01% | -53.8% |
| Q2 2023 | $133,280 | -16.5% | 28,000 | 0.0% | 0.01% | -23.5% |
| Q1 2023 | $159,600 | -43.5% | 28,000 | 0.0% | 0.02% | -45.2% |
| Q4 2022 | $282,520 | -54.9% | 28,000 | 0.0% | 0.03% | -55.7% |
| Q3 2022 | $627,000 | -27.8% | 28,000 | 0.0% | 0.07% | -18.6% |
| Q2 2022 | $869,000 | -20.0% | 28,000 | 0.0% | 0.09% | -15.7% |
| Q1 2022 | $1,086,000 | -10.4% | 28,000 | 0.0% | 0.10% | -6.4% |
| Q4 2021 | $1,212,000 | -29.3% | 28,000 | 0.0% | 0.11% | -28.3% |
| Q3 2021 | $1,715,000 | -29.4% | 28,000 | 0.0% | 0.15% | -37.4% |
| Q2 2021 | $2,430,000 | +5.2% | 28,000 | 0.0% | 0.24% | -6.9% |
| Q1 2021 | $2,309,000 | -9.3% | 28,000 | 0.0% | 0.26% | -22.6% |
| Q4 2020 | $2,546,000 | +138.6% | 28,000 | 0.0% | 0.34% | +106.7% |
| Q3 2020 | $1,067,000 | +3.6% | 28,000 | 0.0% | 0.16% | -6.3% |
| Q2 2020 | $1,030,000 | +65.6% | 28,000 | 0.0% | 0.17% | +1.8% |
| Q1 2020 | $622,000 | – | 28,000 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $83,733,000 | 21.39% |
| Redmile Group, LLC | 12,957,222 | $321,080,000 | 12.26% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $25,703,000 | 5.81% |
| Casdin Capital, LLC | 2,100,000 | $52,038,000 | 4.40% |
| Ally Bridge Group (NY) LLC | 181,500 | $4,498,000 | 4.10% |
| DAFNA Capital Management LLC | 550,940 | $13,652,000 | 3.72% |
| Artal Group S.A. | 2,600,000 | $64,428,000 | 3.44% |
| Deep Track Capital, LP | 2,018,005 | $50,006,000 | 3.29% |
| HighVista Strategies LLC | 118,778 | $2,943,000 | 1.78% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,917 | $158,000,000 | 1.65% |